ghk cu bakersfield GHK-CU - Research Peptide GHK-Cu - Oxo Peptides

doi: 10.1038/s41598-018-24717-0 21

A 2019 review in Nutrients examining NAD+ precursor safety in human clinical trials found oral NMN and NR well-tolerated at doses up to 1,000 mg/day with no serious adverse events reported

Research indicates that GHK-Cu is generally well-tolerated in animal models when administered within the recommended doses

It was first isolated from human plasma in 1973 by researcher Loren Pickart, who discovered that older human serum caused liver cells to behave more like younger cells

The benefits of GHK in terms of long-term effects on slowing aging could have a high impact on increasing the quality of life with increasing age